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AbsTrACT
Objective current strategies to guide selection of 
neoadjuvant therapy in oesophageal adenocarcinoma 
(Oac) are inadequate. We assessed the ability of 
a Dna damage immune response (DDir) assay to 
predict response following neoadjuvant chemotherapy 
in Oac.
Design transcriptional profiling of 273 formalin-fixed 
paraffin-embedded prechemotherapy endoscopic Oac 
biopsies was performed. all patients were treated 
with platinum-based neoadjuvant chemotherapy and 
resection between 2003 and 2014 at four centres in the 
Oesophageal cancer clinical and Molecular Stratification 
consortium. cD8 and programmed death ligand 1 
(PD-l1) immunohistochemical staining was assessed in 
matched resection specimens from 126 cases. Kaplan-
Meier and cox proportional hazards regression analysis 
were applied according to DDir status for recurrence-
free survival (rFS) and overall survival (OS).
results a total of 66 Oac samples (24%) were DDir 
positive with the remaining 207 samples (76%) being 
DDir negative. DDir assay positivity was associated 
with improved rFS (Hr: 0.61; 95% ci 0.38 to 0.98; 
p=0.042) and OS (Hr: 0.52; 95% ci 0.31 to 0.88; 
p=0.015) following multivariate analysis. DDir-positive 
patients had a higher pathological response rate 
(p=0.033), lower nodal burden (p=0.026) and reduced 
circumferential margin involvement (p=0.007). no 
difference in OS was observed according to DDir status 
in an independent surgery-alone dataset. DDir-positive 
Oac tumours were also associated with the presence 
of cD8+ lymphocytes (intratumoural: p<0.001; stromal: 
p=0.026) as well as PD-l1 expression (intratumoural: 
p=0.047; stromal: p=0.025).
Conclusion the DDir assay is strongly predictive of 
benefit from Dna-damaging neoadjuvant chemotherapy 
followed by surgical resection and is associated with a 
proinflammatory microenvironment in Oac.
InTrODuCTIOn
The incidence of oesophageal adenocarci-
noma  (OAC) in the Western world has risen sixfold 
in the last 40 years with the highest incidence occur-
ring in the UK.1–3 In resectable cases, the addition 
of neoadjuvant or perioperative therapy provides a 
modest improvement in overall survival (OS), but 
only 15% of patients demonstrate a histopatholog-
ical response to therapy in the resected tumour.4–7 
significance of this study
What is already known on this subject?
 ► Neoadjuvant therapy followed by surgical 
resection cures less than half of patients with 
resectable oesophageal adenocarcinoma (OAC).
 ► Response rates to neoadjuvant platinum-based 
chemotherapy are low at 15%.
 ► Recent molecular landscape studies in OAC 
have indicated the presence of a DNA damage 
response impaired subgroup of tumours.
What are the new findings?
 ► A 44-gene DNA damage immune response 
(DDIR) assay can successfully be applied to 
formalin-fixed paraffin-embedded pretreatment 
endoscopic biopsies with a success rate 
of >98%.
 ► The DDIR assay is predictive of response and 
survival benefit following DNA-damaging 
neoadjuvant chemotherapy and surgery.
 ► DDIR-positive patients have increased 
pathological response, lower nodal burden and 
reduced resection margin involvement.
 ► DDIR positivity is associated with an 
inflammatory microenvironment characterised 
by the presence of CD8-positive tumour-
infiltrating lymphocytes and high programmed 
death ligand 1 expression.
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Despite improvements in oncological and surgical management, 
the majority of patients relapse and die of their cancer.4–6 There-
fore, there is a pressing need to identify biomarkers capable of 
predicting response in order to select the appropriate neoadju-
vant therapy for individual patients.
Imaging and molecular features of OAC have been studied 
in an attempt to identify predictive biomarkers to neoadjuvant 
therapy. For example, serial [18F]−2-fluoro-2-deoxy-d-glucose 
(18FDG) positron emission tomography (FDG-PET) scans can 
detect changes in tumour metabolism with the aim of predicting 
pathological response.8–10 A 35% reduction in standard uptake 
value (SUV) 14 days after baseline has been correlated with a 
higher rate of tumour regression, R0 resection and improved 
survival in a prospective study of resectable OAC.9 However, 
42% of FDG-PET responders identified by a reduction in SUV 
did not in fact achieve a pathological response, highlighting the 
pressing need to identify more accurate molecular predictive 
biomarkers. Various proposed single gene predictive biomarkers, 
such as nuclear-factor-κβ, epidermal growth factor receptor, 
TP53, ERCC1 and thymidylate synthase, have met with limited 
success as they fail to capture the complex biology of OAC.11–18 
Recent advances in the molecular understanding of OAC have 
demonstrated that it is a disease characterised by a high level of 
mutations and copy number changes giving rise to prominent 
intratumoural heterogeneity.19–22 To encapsulate the biology 
underpinning response to chemotherapy in OAC, a number of 
studies have applied gene expression profiling to pretreatment 
endoscopic biopsies to identify a predictive gene signature.23–25 
However, these signatures rely on fresh frozen tissue, which 
is not routinely available, and have been developed in small 
discovery cohorts without independent validation.
The DNA damage immune response (DDIR) assay, formerly 
known as the DNA Damage Response Deficiency assay, was 
previously developed in breast cancer using an unsupervised hier-
archical clustering approach.26 When tested in an independent 
breast cancer dataset (n=203), DDIR positivity was associated 
with an OR for pathological response following neoadjuvant 
chemotherapy of 3.96 (95% CI 1.67 to 9.41; p=0.002), and 
in a cohort of 191 patients with node-negative breast cancer, 
the assay predicted 5-year disease-free survival following adju-
vant chemotherapy with an HR of 0.37 (95% CI 0.15 to 0.88; 
p=0.025). Further validation in 664 chemo-naive patients indi-
cated that the DDIR assay was not prognostic and only predicts 
outcome in the context of DNA-damaging chemotherapy. 
Biologically, the DDIR assay indicates constitutive activation 
of the cyclic GMP-AMP synthase (cGAS)/stimulator of inter-
feron genes (STING) pathway in response to endogenous DNA 
damage.27 Deficiencies in DNA repair and the Fanconi anaemia/
BRCA pathway in particular have been reported to activate 
this pathway. Importantly, the 44-gene DDIR assay includes 
well-known immune checkpoint targets, such as programmed 
death ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase 1, as 
well as several inflammatory cytokines. Immune activation via 
the STING pathway results in infiltration of the tumour by T 
lymphocytes and upregulation of immune checkpoints to create 
an inflammatory microenvironment associated with chemosensi-
tivity. However, pathological response (tumour regression grade 
[TRG] 1/2) to DNA-damaging chemotherapy and chemoradio-
therapy occurs in only 15% and 23% of OAC tumours, respec-
tively.6 7 We hypothesised that pathological tumour response and 
improved survival may be due to pre-existing deficiencies in DNA 
repair pathways with associated activation of an innate immune 
response. An assay that could identify this subgroup of OAC 
tumours would predict benefit from neoadjuvant chemotherapy.
We, therefore, assessed the ability of the DDIR assay to predict 
pathological response and prognosis following DNA-damaging 
neoadjuvant chemotherapy in OAC. We demonstrate that the 
DDIR assay can be applied to routine diagnostic clinical spec-
imens to allow the selection of patients for whom DNA-dam-
aging chemotherapy would be beneficial. DDIR positivity is 
also strongly correlated with the presence of tumour-infiltrating 
lymphocytes (TILs) and PD-L1 expression indicating an associ-
ation between deficiencies in DNA damage repair mechanisms 
and a proinflammatory microenvironment in OAC.
MATerIAls AnD MeThODs
This study was performed according to the REporting recom-
mendations for tumour MARKer prognostic studies (REMARK) 
as outlined in the criteria checklist (online supplementary table 
1) and REMARK study design diagram (online supplementary 
figure 1 and online appendix A)
Patient samples
FFPE prechemotherapy endoscopic biopsies from 273 patients 
with resectable OAC, treated with neoadjuvant chemotherapy 
followed by surgical resection, were collected at four UK centres 
in the Oesophageal Cancer Clinical and Molecular Stratification 
(OCCAMS) consortium between 2003 and 2014 (online supple-
mentary table 2). Follow-up was performed according to local 
institutional guidelines. Patients with localised histologically 
confirmed adenocarcinoma of the oesophagus or gastro-oesoph-
ageal junction were included, and all patients were followed up 
for at least 2 years. Pathological response was assessed in the 
matched resection specimens according to the method described 
by Mandard et al with a responder defined as TRG ≤2.7 28 
Assuming a marker positive rate of 21% (estimated from prelim-
inary data), a sample set of 273 patients had an 80% power to 
detect a HR of 2.
For independent in silico validation, a publicly available 
dataset of 57 OAC resections that did not receive DNA-damaging 
chemotherapy (GSE19417) was assessed (online supplementary 
table 3). All tumour samples were collected and snap-frozen from 
patients undergoing potentially curative surgical resection at the 
Bristol Royal Infirmary between 1992 and 2000. Gene expres-
sion profiling was performed using a custom-made Agilent 44K 
60-mer oligomicroarray as previously described.29
Gene expression profiling from FFPe tissue
Biopsies were reviewed for pathological subtype prior to marking 
for macrodissection and samples containing at least 50% adeno-
carcinoma tissue by area were taken forward. Where tumour 
material was limited endoscopic biopsy fragments from the same 
significance of this study
how might it impact on clinical practice in the foreseeable 
future?
 ► The ability to select the appropriate neoadjuvant therapy 
for individual patients with OAC could increase pathological 
response rates and survival.
 ► Ineffective therapy could be avoided in patients with OAC 
unlikely to respond.
 ► Insights into the molecular biology of the DDIR subgroup will 
allow novel combinations of conventional therapy with DNA 
repair inhibitors or immunotherapy to be explored.
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patient were pooled. Total RNA was extracted using the Recov-
erall Total Nucleic Acid Isolation Kit for FFPE (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) and amplified using 
the NuGen Ovation FFPE Amplification System v3 (NuGen San 
Carlos, California, USA). The amplified product was hybridised 
to the Almac Diagnostics Xcel array (Almac, Craigavon, UK), 
a cDNA microarray-based technology optimised for archival 
FFPE tissue and analysed using the Affymetrix Genechip 7G 
scanner (Affymetrix, Santa Clara, California, USA) as previously 
described.26 30 Functional enrichment was performed using the 
Database for Annotation, Visualization and Integrated Discovery. 
Raw expression data are available at the Array Express reposi-
tory (Accession Number E-MTAB-6969).
Immunohistochemistry (IhC)
Matched FFPE OAC resection specimens were available for 
126 patients who received neoadjuvant chemotherapy prior to 
surgical resection at the Northern Ireland Cancer Centre. Patho-
logical staging was defined according to International Union 
Against Cancer TNM Staging, 7th Edition, and the cases had a 
median follow-up time of 48.8 months (online supplementary 
table 4). All cases were represented in triplicate, and the Tissue 
Microarray (TMA) was constructed as previously described.31 32
Antibodies to CD8 (C8/144B, M7103, Dako) and PD-L1 
(SP142, Roche) were used as previously described.27 TMA 
sections were scored by two independent observers (EEP and 
EM) who were blinded to the clinical data. A semiquantitative 
scoring system was used for CD8+ expression with a score of 
3 indicating strong CD8+ expression, 2 moderate expression, 
1 weak expression and 0 absence of expression. For PD-L1, 
tumour and stroma were scored for percentage of cells with 
positive expression and previously published cut-offs of 1% or 
greater and 5% or greater were used for analysis.33
Whole genome sequencing
Matched whole genome sequencing data were available for 
44 patients who received neoadjuvant chemotherapy prior to 
surgical resection at three OCCAMS centres (Cambridge, Edin-
burgh and Southampton; online supplementary table 4).
Whole genome sequencing was performed, and mutational 
signatures were identified using the non-negative matrix factori-
sation (NMF) methodology as previously described.22 34
statistical analysis
Microarray data were preprocessed using the Robust Multi-
array Average model for the Almac Diagnostics Xcel array with 
DDIR signature scores calculated and predefined cut-points 
applied as previously described.26 A threshold of 0.3403 was 
optimised in an independent technical study of n=45 OAC 
samples and applied independently to the validation cohort 
dichotomising patients as DDIR positive (>0.3403) or DDIR 
negative (≤0.3403). Cox proportional hazards regression was 
used to investigate the prognostic effects of the DDIR signature 
on relapse-free survival (RFS) and OS defined as the time from 
surgical resection to relapse of disease or death from any cause, 
respectively. The estimated effect of the signature was adjusted 
for factors available at the time of diagnosis (clinical tumour 
status, clinical nodal status and tumour grade) by fitting a multi-
variate model.
Further details are available in the online supplementary 
methods.
resulTs
Assessment of the DDIr assay and survival following 
neoadjuvant chemotherapy and surgical resection in OAC
To assess the ability of the DDIR assay to predict survival 
following neoadjuvant DNA-damaging chemotherapy and resec-
tion in OAC, it was applied to a retrospective dataset of 273 
FFPE biopsy samples. A total of 66 OAC samples (24%) were 
characterised as DDIR positive with the remaining 207 (76%) 
being DDIR negative. Reductions in lymph node and circumfer-
ential resection margin (CRM) involvement, a more proximal 
tumour location and older age were observed for DDIR posi-
tive tumours (table 1). DDIR assay positivity was associated with 
improved RFS (HR 0.58, 95% CI 0.38 to 0.90; p=0.015) and 
OS (HR 0.62, 95% CI 0.41 to 0.95; p=0.029) following surgical 
resection (figure 1). When evaluated as a continuous variable, 
higher DDIR scores were associated with both improved RFS 
(HR 0.34, 95% CI 0.13 to 0.93; p=0.036) and OS (HR 0.32, 
95% CI 0.12 to 0.87; p=0.026). Univariate analysis confirmed 
associations between survival and presurgical clinical N stage 
as well as postsurgical factors such as pathological T and N 
stage, differentiation, lymphovascular invasion and CRM status 
(online supplementary table 5). Applying a published cut-off 
of ≥15 lymph nodes to indicate an adequate lymph node yield, 
we found that there was no association between the DDIR status 
and lymph node yield and neither was there an association 
between adequate lymph node yield and RFS (HR 0.94, 95% CI 
0.66 to 1.39; P=0.847) or OS (HR 1.02, 95% CI 0.7 to 1.48; 
p=0.916). While the Lauren classification is known to be prog-
nostic in OAC, it was not available for the whole cohort and so it 
is unclear how the DDIR assay relates to intestinal versus diffuse 
type adenocarcinomas.35 Also, there was no association between 
the administration of postoperative chemotherapy and DDIR 
status (HR 0.74, 95% CI 0.39 to 1.4; p=0.354), but there was 
a trend towards improved OS in DDIR-positive patients when 
no adjuvant chemotherapy was administered (HR 0.39, 95% CI 
0.15 to 1.02; p=0.55) (online supplementary figure 2).
Multivariable analysis was performed to test the association 
between DDIR status and each survival endpoint following 
adjustment for factors available at diagnosis (table 2). DDIR-pos-
itive patients had improved RFS relative to DDIR negative 
patients (HR 0.61, 95% CI 0.38 to 0.98; p=0.042), and assay 
positivity was also independently associated with improved OS 
(HR 0.52, 95% CI 0.31 to 0.88; p=0.015).
To assess whether the DDIR assay was prognostic, indepen-
dent of DNA-damaging chemotherapy treatment, it was applied 
to a publicly available dataset of 57 OAC resections, which did 
not receive neoadjuvant chemotherapy (online supplementary 
table 3). No significant difference in overall survival was noted 
between the DDIR-positive and DDIR-negative populations 
(HR 0.86, 95% CI 0.48 to 1.55; p=0.61) (online supplemen-
tary figure 3). However, further confirmatory results in a larger 
cohort are required. Taken together, these results indicate that 
the DDIR assay is a strong predictor of survival benefit following 
surgical resection in OAC, but only in the context of neoadju-
vant DNA-damaging chemotherapy.
The DDIr assay is predictive of pathological response in OAC
The ability to predict pathological response to neoadjuvant 
chemotherapy would improve patient stratification and treat-
ment selection in OAC. TRG was available for 228 patients in the 
OAC cohort with 24 (11%) of cases having a TRG ≤2, indicating 
a pathological response, and 203 (89%) TRG 3–5, in keeping 
with limited or no response to chemotherapy. Pathological 
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Table 1 Association of clinicopathological characteristics with DDIR status in the OAC cohort
DDIr positive (n=66) DDIr negative (n=207)
P valuen % n %
Age (years)
  <60 14 21.2 56 27.1 0.035
  60–69 20 30.3 92 44.4
  ≥70 24 36.4 47 22.7
  Unknown 8 12.1 12 5.8
  Median 66 64 0.049
  Range 41–79 28–83
Sex
  Male 54 81.8 168 81.2 0.905
  Female 12 18.2 39 18.8
Tumour site
  Oesophagus 15 22.7 18 8.7 0.009
  GOJ, Siewert 1 27 40.9 103 49.8
  GOJ, Siewert 2 14 21.2 64 30.9
  GOJ, Siewert 3 10 15.2 22 10.6
Clinical T stage
  cT1 1 1.5 3 1.4 0.936
  cT2 8 12.1 20 9.7
  cT3 48 72.7 160 77.3
  cT4 2 3 6 2.9
  Unknown 7 10.6 18 8.7
Clinical N stage
  N0 12 18.2 50 24.2 0.378
  N1 39 59.1 121 58.5
  N2 6 9.1 10 4.8
  N3 3 4.5 5 2.4
  Unknown 6 9.1 21 10.1
Pathological T stage
  ypT0 6 9.1 6 2.9 0.1
  ypT1 11 16.7 20 9.7
  ypT2 10 15.2 32 15.5
  ypT3 36 54.5 139 67.1
  ypT4 3 4.5 10 4.8
Pathological N stage
  ypN0 33 50 69 33.3 0.026
  ypN1 9 13.6 52 25.1
  ypN2 16 24.2 42 20.3
  ypN3 8 12.1 44 21.3
Lymph node yield
  ≥15 45 68.2 151 72.9
  <15 21 31.8 55 26.6 0.433
  Unknown 0 0 1 0.5
  Median 21.5 21 0.863†
  Range 6–41 6–62
Differentiation
  Well 4 6.1 3 1.4 0.044
  Moderate 16 24.2 74 35.7
  Poor 40 60.1 121 58.5
  Unknown 6 9.1 9 4.3
Lymphovascular invasion
  Negative 25 37.9 61 29.5 0.222
  Positive 39 59.1 139 67.1
  Unknown 2 3 7 3.4
Circumferential resection margin
  Negative 47 71.2 111 53.6 0.007
Continued
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response was observed in 16.7% and 6.8% of DDIR-positive and 
DDIR-negative cases, respectively (p=0.025) (table 1). DDIR 
scores were grouped by response status and one-way analysis 
of variance analysis demonstrated significantly higher DDIR 
scores in responders compared with non-responders (p=0.033). 
This indicates that the DDIR score was significantly enriched 
for tumours that respond to neoadjuvant chemotherapy in OAC 
(figure 2).
DDIr assay positivity and tumour mutational load
Recent sequencing studies have stratified OAC into subtypes 
defined by the pattern of somatic mutations. Secrier et al22 iden-
tified three subgroups (C>A/T dominant, DNA damage response 
[DDR] impaired and mutagenic through the application of muta-
tional signatures to WGS data from a cohort of 129 chemothera-
py-naïve OAC samples. We sought to assess the overlap between 
cases defined as DDIR positive by our gene expression assay and 
DDR impaired by mutational signature analysis. A total of 44 
cases had matched gene expression and WGS data available and 
demonstrated higher clinical nodal staging and different neoad-
juvant chemotherapy regimens compared with the whole cohort 
and the tissue microarray (TMA) subset (online supplementary 
table 4). This may reflect differing staging methodologies used 
at the largest contributing centre to the WGS cohort (Univer-
sity of Cambridge; 29 [66%] of patients) and the increased use 
of cisplatin and oxaliplatin doublet neoadjuvant regimens due 
to clinical trials recruiting at that centre at the time of sample 
collection (OEO536 and LEO37).
NMF was applied to cluster the patients into the three 
subgroups (online supplementary figure 4). No association 
was observed between the DDIR status and the predominant 
mutational signature (online supplementary table 6; p=0.83). 
Although the size of the cohort limits the statistical power of 
the analysis, DDIR-positive patients did display a trend towards 
higher tumour mutational burden and a higher mutation rate 
(online supplementary figure 5). However, no significant differ-
ences were observed in the mean copy number or total number 
of deleterious somatic mutations or indels in multiple DDR path-
ways between the DDIR-positive and DDIR-negative samples. 
Neither were there any differences observed in the copy number 
of genes involved in the homologous recombination, double and 
single strand break repair pathways (data not shown). While 
both assays are related to loss of DNA repair, the assessment of 
differing biologies represented by immune activation in response 
to DNA damage measured by the DDIR assay, as opposed to the 
pattern of mutations caused by deficiencies in DNA repair mech-
anisms may lead to the lack of association.
DDIr assay positivity is associated with CD8+ T lymphocytes 
and expression of PD-l1
We hypothesised that increased DNA damage in DDIR-positive 
tumours may be associated with increased lymphocytic infiltration 
and upregulation of immune checkpoint genes. A list of 45 genes 
differentially expressed between DDIR-positive and DDIR-neg-
ative patients, with a fold change of >2, was generated (online 
supplementary table 7). As expected, this list included the genes 
from the DDIR signature, with 5 out of 44 genes represented, 
but it also included a number of genes encoding inflammatory 
cytokines and mediators of an immune response. Chemokines 
such as CXCL9 and CXCL13 showed 5.5-fold and 4.58-fold 
upregulation, respectively, and 29 of the 45 genes (64.4%) have 
a role in the immune response. Pathway analysis demonstrated 
enrichment of a wide range of biological processes related to 
immune activation and viral response (online supplementary 
table 8), further strengthening the association of DDIR-positive 
status with a proinflammatory microenvironment.
To assess the relationship between DDIR status, PD-L1 expres-
sion and the presence of TILs, we performed IHC analysis on 
126 resection specimens matched to patients in the gene expres-
sion cohort (figure 3, table 3, online supplementary tables 9 
and 10). Previously, published cut-offs of 1% or greater and 5% 
or greater were used to define PD-L1 positivity. A statistically 
significant association was observed between DDIR assay posi-
tivity and intratumoural and stromal PD-L1 expression at the 
5% cut-off (p=0.047; p=0.25, respectively). The presence of 
both intratumoural and stromal CD8+ TILs was also associated 
with DDIR assay positivity (p<0.001; p=0.026, respectively).
DDIr positive (n=66) DDIr negative (n=207)
P valuen % n %
  Positive 15 22.7 85 41.1
  Unknown 4 6.1 11 5.3
Neoadjuvant chemotherapy
  CFU/CX 12 18.2 33 15.9 0.89
  ECF/X 52 78.8 168 81.2
  Oxaliplatin/X 1 1.5 4 1.9
  Unknown 1 1.5 2 1
Adjuvant chemotherapy received
  No 12 18.2 48 23.2 0.448
  Yes 26 39.4 75 36.2
  Unknown 28 42.4 84 40.6
Pathological response
  Responder 11 16.7 14 6.8 0.025
  Non-responder 45 68.2 158 76.3
  Unknown 10 15.2 35 16.9
Mann-Whitney U test.
CFU, cisplatin and 5-fluorouracil; CX, cisplatin and capecitabine (xeloda); DDIR, DNA damage immune response; ECF/X, epirubicin, cisplatin and 5-fluorouracil/capecitabine 
(xeloda); GOJ, gastro-oesophageal junction; OAC, oesophageal adenocarcinoma; Oxaliplatin/X, oxaliplatin and capecitabine (xeloda).
Table 1 Continued
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DIsCussIOn
We have demonstrated that the DDIR assay is predictive of 
response and independently prognostic following DNA-dam-
aging neoadjuvant chemotherapy and surgical resection in OAC. 
DDIR assay positivity was associated with improved survival 
following chemotherapy and surgery and identified those 
patients with a higher probability of obtaining a pathological 
response, reduced nodal burden and clear resection margins. 
When assessed alongside clinical factors available at the time of 
diagnosis, DDIR status demonstrated superior prognostic ability 
compared with standard clinicopathological factors. Application 
of the DDIR assay to a cohort of patients who did not receive 
neoadjuvant therapy demonstrated no difference in survival 
according to DDIR status indicating that the DDIR assay may 
not be prognostic in its own right but only in the context of 
DNA-damaging therapy.
Our study has a number of advantages compared with prior 
attempts to identify a predictive biomarker to neoadjuvant 
therapy in OAC. Previous biomarker studies have relied on fresh 
frozen tissue, which is not routinely collected, and suffered from 
high attrition rates for samples analysis. However, our study used 
FFPE diagnostic tissue with a success rate of 95.8% in samples 
submitted for analysis, allowing the assay to be readily applied to 
clinical practice. Other attempts to develop a predictive classifier 
have also been limited by small sample size and lack of suitable 
validation sets.23–25 38 We were able to validate the DDIR assay 
in a sufficiently powered real-world cohort of patients to assess 
its predictive ability, and the assay has also undergone extensive 
analytical validation enabling it to be reproducibly applied to 
clinical samples.
Limitations of the study include the use of a retrospective 
clinical cohort that may influence survival outcomes due to the 
absence of standardised follow-up procedures and so the DDIR 
assay will require further validation in a randomised controlled 
trial dataset and by a prospective study. Also, all patients were 
Figure 1 Kaplan-Meier curves stratified by the DDIR assay for 
(A) relapse-free and (B) overall survival for 273 patients with 
oesophageal adenocarcinoma treated with cisplatin-based neoadjuvant 
chemotherapy followed by surgical resection. DDIR, DNA damage 
immune response.
Table 2 Multivariate analysis and combined model of clinicopathological factors, DDIR status, relapse-free and overall survival in OAC
relapse-free survival Overall survival
hr 95%  CI P value hr 95%  CI P  value 
Multivariate model
  DDIR positive 0.61 0.38–0.98 0.042 0.52 0.31–0.88 0.015
  Clinical T stage
  (T1/2 v 3/4)
1.08 0.56–2.09 0.810 1.05 0.55–2.03 0.876
  Clinical N stage
  (N0 v 1/2/3)
1.67 1.04–2.67 0.033 1.51 1.94–2.42 0.088
  Differentiation
  (well/moderate vs poor)
1.32 0.91–1.92 0.146 1.43 0.97–2.10 0.071
DDIR, DNA damage immune response; OAC, oesophageal adenocarcinoma. 
Figure 2 Boxplot of DDIR scores grouped by response 
status. DDIR, DNA damage immune response.
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treated with neoadjuvant platinum-based chemotherapy prior to 
surgical resection. Considering neoadjuvant chemoradiotherapy 
is standard practice in the USA and many parts of Europe; 
further validation is required in a sample set treated with this 
modality. An additional challenge for many biomarker studies is 
the heterogeneity demonstrated by OAC. A high level of intra-
tumoural heterogeneity has been correlated with response to 
neoadjuvant chemotherapy in OAC and has indicated the limita-
tions of a single biopsy to develop a predictive biomarker.39 This 
may be partially mitigated in our study by the pooling of endo-
scopic biopsy fragments with sufficient tumour material, but only 
samples from multiple sites within the tumour could encompass 
the underlying clonality of OAC tumours. The limited amount 
of tumour tissue available in the biopsy samples also precluded 
their use in the analysis of TILs and PD-L1 expression and so 
matched resection specimens were used. However, the prior 
administration of neoadjuvant chemotherapy may have influ-
enced the amount of TILs present and the expression levels of 
PD-L1 in these specimens.
With regard to the clinical applicability of the assay, a number 
of factors should be taken into consideration. The response rate 
of 16.7% observed in DDIR-positive patients was significantly 
higher than that observed in DDIR-negative patients (6.8%), 
but is comparable with unselected published retrospective and 
clinical trial cohorts.4 7 This may limit the utility of the assay 
as a tool to enhance pathological response following neoad-
juvant chemotherapy. Conversely, a response rate of 6.8% in 
DDIR-negative patients may not be low enough to dissuade 
clinicians from using neoadjuvant cisplatin-based chemotherapy 
in this patient population. Data from other cancer types indi-
cating an increase in response following taxane treatment in 
tumours with intact DNA repair mechanisms may provide a 
rationale for the use of the docetaxel, oxaliplatin, fluorouracil/
leucovorin chemotherapy (FLOT) regimen in DDIR-negative 
patients. For example, ovarian cancer patients with low/interme-
diate levels of BRCA1 have improved survival following treat-
ment with platinum-based chemotherapy, whereas high levels of 
BRCA1 expression correlate with improved OS following the 
use of taxane-contatining chemotherapy.40 Similarly, in breast 
cancer cell lines, exogenous expression of BRCA1 increased 
sensitivity to spindle poisons, such as paclitaxel and vinorel-
bine.41 We would hypothesise that DDIR-positive patients may 
benefit from the direct damage to DNA induced by cisplatin 
or radiotherapy, whereas the DDIR-negative cases may also 
require the addition of inhibitors of microtubule formation, 
such as docetaxel. Testing of the assay in sufficiently powered 
randomised trial cohorts containing suitable treatment regimens 
could answer such a question. Further considerations regarding 
the utility of the assay include the association of DDIR positivity 
with older patients that could indicate an increased prevalence 
of this proinflammatory subgroup with increasing age. Also, the 
trend towards increased survival for DDIR-positive patients who 
do not receive adjuvant chemotherapy should be interpreted 
with caution as it is likely to be confounded by patients who 
had an excellent pathological response not going on to receive 
further chemotherapy.
The biology of a DNA repair-deficient subgroup should be 
examined in the context of recent publications from collabo-
rative sequencing efforts that have characterised the molecular 
Figure 3 Immunohistochemistry images (×10; inset ×40) showing 
absence of CD8+ lymphocytes and PD-L1 staining in DDIR assay-
negative tumours. Both intratumoural and stromal CD8+ lymphocytes 
were observed in DDIR assay-positive tumours along with PD-L1 
tumours. Scale bar represents 50 µM. DDIR, DNA damage immune 
response; PD-L1, programmed death ligand 1.
Table 3 CD8+ intratumoural and stromal lymphocytic infiltrate and 
PD-L1 staining assessed by IHC in DDIR-positive and DDIR-negative 
tumours
DDIr positive
(n=24)
DDIr negative
(n=102)
P valuen % n %
Intratumoural
  PD-L1
   ≥1% 7 29.2 10 9.8 0.02
   <1% 17 70.8 92 90.2
   ≥5% 3 12.5 2 2 0.047
   <5% 21 70.8 100 90.2
  CD8+
   3 1 4.2 0 0 <0.001
   2 4 16.7 1 1
   1 14 13.7 63 61.7
   0 5 4.9 38 37.2
Stromal
  PD-L1
   ≥1% 17 70.8 52 51 0.11
   <1% 7 29.2 50 49
   ≥5% 8 33.3 12 11.8 0.025
   <5% 16 66.7 90 88.2
  CD8+
   3 8 33.3 10 9.8 0.026
   2 8 33.3 45 44.1
   1 8 33.3 44 43.1
   0 0 0 3 2.9
DDIR, DNA damage immune response; PD-L1, programmed death ligand 1.
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landscape of oesophagogastric adenocarcinoma.19 20 42 43 Multiple 
platform analysis by The Cancer Genome Atlas has identified 
four subgroups within oesophagogastric adenocarcinoma with 
tumours of the distal oesophagus and gastro-oesophageal junc-
tion characterised by chromosomal instability, a paucity of onco-
genic driver mutations and frequent amplifications of upstream 
activators of signalling pathways.19 42 43 Within the stomach, 
tumours may also be of the genomically stable or mismatch 
repair subtype with the final subgroup of Epstein-Barr virus 
(EBV)-positive tumours occurring in the distal stomach.42 43 
Mutational signature analysis of whole genome sequencing data 
from 129 chemotherapy-naïve OAC samples has revealed three 
subgroups demonstrating either deficiencies in DNA damage 
repair, high mutational burden or a C>A/T mutational pattern.22 
The DDR-impaired subgroup constitutes 20% of patients with 
OAC and, while this is in keeping with a DDIR positive rate 
of 24%, our analysis has shown no significant overlap between 
the two subgroups. Reasons for this discrepancy could include 
the differing methodologies used to define DNA repair defects 
between the sequencing and gene expression dataset, the lack 
of a defined cut-point to call DDR impaired status in the WGS 
data and the limited sample size. Also, the DDIR assay takes a 
functional approach, capturing the inflammatory response acti-
vated by DNA damage, whereas analysis of the sequencing data 
assesses the pattern of mutations that occur as a result of loss 
of DNA repair. Furthermore, Janjigian et al performed prospec-
tive sequencing of 295 patients with metastatic oesophagogas-
tric cancer using a capture-based next-generation sequencing 
(NGS) platform capable of detecting mutations, copy number 
alterations and selected rearrangements in up to 468 cancer 
genes. No single mutant allele or gene with a role in DNA repair 
was associated with immune response, and a surrogate marker 
of homologous recombination deficiency, termed the large 
scale transition (LST) score, was not associated with improved 
progression-free survival (HR 0.99, p=0.947) following first-
line platinum-based chemotherapy. Higher LST scores were not 
observed in patients with response to first-line therapy lasting 
over 24 months (p=0.6) and neither did the majority of patients 
with prolonged responses harbour somatic alterations in know 
HR genes. Conversely, Smyth et al showed that assessment of 
homologous recombination deficiency using a genomic signature 
for loss of heterozygosity (LOH) derived from an NGS panel 
could identify a high LOH group of patients with prolonged 
survival following platinum-based chemotherapy.44 However, 
this study was limited by a high attrition rate for LOH inference 
(47% of samples successfully scored) and small sample numbers. 
A possible explanation for these results is the limitations imposed 
by targeted platforms that are unable to detect alterations in 
genes absent from the panel as well as epigenetic and transcrip-
tional consequences of somatic mutations. Previous studies in 
breast cancer have shown that while BRCA1/2 mutations may 
confer sensitivity to DNA-damaging chemotherapy, this is not 
true for all cases as not all mutations may affect DNA repair or 
may be compensated for by alternate mechanisms.45 Conversely, 
BRCA1/2 wild-type tumours can possess an abnormal DNA 
damage response due to epigenetic silencing of BRCA1/2.46 47 
Therefore, it is likely that the transcriptome-based DDIR assay 
is capable of capturing the downstream effects of genomic and 
epigenetic changes and so detect a broader range of mechanisms 
of DDR impairment. It is clear that a subgroup of patients with 
DNA repair deficiencies exists within OAC, and further work is 
needed to accurately characterise this patient group.
Recently, the field of DNA repair biology has enjoyed renewed 
interest due to its involvement in the immune response to cancer. 
Increased DNA damage within cancer cells has been shown to 
generate a highly immunogenic state within the tumours leading 
to the presence of TILs and the upregulation of suppressors 
of the immune response, such as PD-L1.48 Our data indicate a 
strong association between DDIR positivity and an immuno-
genic microenvironment. Indeed, our group has demonstrated 
the role of the cGAS-STING pathway in the response to DNA 
damage with the resultant upregulation of inflammatory cyto-
kines such as CXCL10 and CCL5 as well as PD-L1.27 The 
STING pathway is activated by cytosolic DNA released from the 
nucleus in response to DNA damage, driving an innate immune 
type 1 interferon response and a subsequent upregulation of 
immune checkpoints including PD-L1, a key component of the 
DDIR signature. Furthermore, the cGAS-STING pathway has 
been shown to be a key player in response to immune checkpoint 
blockade.49 50 In keeping with this, we demonstrated increased 
CD8+ T cell infiltration and PD-L1 expression in DDIR-posi-
tive oesophageal tumours, both of which have been proposed as 
predictive biomarkers for immunotherapy agents.51 52 The pres-
ence of a DNA damage-deficient subgroup in oesophagogastric 
cancer may indicate sensitivity to conventional chemotherapy 
and response to immune checkpoint targeted agents.
In summary we have developed an array-based classifier 
using pretreatment FFPE biopsies to predict benefit from, and 
response to, neoadjuvant therapy in resectable OAC. The assay 
is readily applicable to routine pathological samples with poten-
tial for rapid translation into clinical use. The identification of 
a subgroup of tumours with deficiencies in their DNA repair 
mechanisms will enable these patients to be selected for more 
effective therapy and improve survival outcomes. Also, knowing 
the underlying biology of these tumours allows the possibility 
of further enhancing response to therapy through combina-
tions with novel inhibitors of DNA repair and immunotherapy. 
Overall, the DDIR assay enables treatment selection and patient 
stratification in oesophagogastric adenocarcinoma and may 
improve response to therapy, resection rates and survival in this 
poor prognostic disease.
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